Press Releases – NASDAQ (US) Website

Press Releases

Jan 22, 2018
BeiGene Announces Closing of $800 Million Public Offering    read more...
Jan 17, 2018
BeiGene Announces Pricing of $750 Million Public Offering    read more...
Jan 16, 2018
BeiGene Announces Proposed Public Offering    read more...
Jan 09, 2018
BeiGene and Boehringer Ingelheim Announce Commercial Supply Agreement for Anti-PD-1 Antibody Tislelizumab    read more...
Jan 08, 2018
BeiGene and Mirati Therapeutics Announce Exclusive License Agreement for Sitravatinib in the Asia Pacific Region    read more...
Jan 02, 2018
BeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Hepatocellular Carcinoma    read more...
Dec 18, 2017
BeiGene Initiates Pivotal Trial of PARP inhibitor Pamiparib (BGB-290) in China in Patients with Ovarian Cancer    read more...
Dec 11, 2017
BeiGene Presents Initial Phase 1b Data for BTK Inhibitor Zanubrutinib (BGB-3111) Combined with PD-1 Antibody Tislelizumab (BGB-A317) at the 59th American Society of Hematology Annual Meeting    read more...
Dec 09, 2017
BeiGene Presents Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) in Non-Hodgkin’s Lymphoma at the 59th American Society of Hematology Annual Meeting    read more...
Dec 09, 2017
BeiGene Presents Updated Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) Combined with GAZYVA® (Obinutuzumab) at the 59th American Society of Hematology Annual Meeting    read more...
Dec 04, 2017
BeiGene to Webcast an Analyst and Investor Event from the American Society of Hematology Annual Meeting    read more...
Nov 13, 2017
BeiGene Expands Global Pivotal Program for BTK Inhibitor BGB-3111    read more...
Nov 13, 2017
BeiGene Reports Third Quarter 2017 Financial Results    read more...
Nov 01, 2017
BeiGene Announces Oral Presentation and Posters at the 59th American Society of Hematology Annual Meeting    read more...
Sep 28, 2017
BeiGene Presents Preliminary Phase 1 Data for BGB-A317 in Chinese Patients with Advanced Tumors at the 20th Annual Meeting of CSCO    read more...
Sep 21, 2017
BeiGene Announces Presentation at the 20th Annual Meeting of the Chinese Society of Clinical Oncology    read more...
Sep 11, 2017
BeiGene Presents Preliminary Phase 1 Data for BGB-A317 in Multiple Solid Tumors at the ESMO 2017 Congress    read more...
Sep 08, 2017
BeiGene Presents Preliminary Phase 1/2 Clinical Data on PARP Inhibitor BGB-290 in Patients with Advanced Solid Tumors at the European Society for Medical Oncology 2017 Congress    read more...
Aug 31, 2017
BeiGene Announces Closing of Global Strategic Oncology Collaboration with Celgene Corporation    read more...
Aug 30, 2017
BeiGene Announces Presentations at the European Society for Medical Oncology 2017 Congress    read more...